Novogene Corporation

Novogene provides genomic services and multi-omics solutions with NGS (next-generation sequencing) and bioinformatics expertise, serving academic, biotech, and biopharma researchers worldwide with the largest Illumina-based sequencing capacity in China and 34 NGS-related patents. The company offers comprehensive multi-omics platforms spanning genomics (human whole genome and exome sequencing, plant and animal whole genome and de novo sequencing, microbial whole genome and de novo sequencing, whole plasmid sequencing), transcriptomics (mRNA sequencing, small RNA sequencing, circular RNA sequencing, total RNA sequencing, whole transcriptome sequencing, full-length transcriptome sequencing, prokaryotic RNA sequencing, metatranscriptome sequencing), epigenomics (DNA methylation sequencing, ChIP-seq, RIP-seq), metagenomics (amplicon sequencing, shotgun metagenomics sequencing), single cell and spatial omics (10x single cell gene expression, 10x single cell immune profiling, 10x Visium HD spatial gene expression, premade library sequencing on Illumina, Element, and PacBio sequencers), proteomics (Olink proteomics), and metabolomics (untargeted metabolomics). Novogene also offers accredited and validated clinical research sequencing for translational research. The company provides an automated delivery platform (Falcon) for streamlined NGS workflows, a bioinformatics analysis tool (NovoMagic) for high-performance data analysis, and a customer service system (CSS) for project management. Novogene has served 8,000+ organizations, processes 3 million+ samples annually, and has contributed to 40,000+ scientific publications. The company serves applications in cancer research, immuno-oncology, agrigenomics, environment, food science, human microbiome, plant and animal microbiome, drug discovery and development, and rare and complex diseases, with European operations based in Cambridge, UK (ISO 14001 certified) and Germany. Founded in 2011 and headquartered in Beijing, China, Novogene has raised $75 million in a Series B round backed by SDIC Innovation, CMB International Capital, Sigma Square Capital, China Merchants Capital, HongShan (Sequoia Capital China), and Europa.